Prelude Therapeutics (PRLD) Cash from Investing Activities (2019 - 2026)

Prelude Therapeutics has disclosed Cash from Investing Activities across 8 years of filings, most recently posting $8.5 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $8.5 million, down 86.33% year-over-year; the trailing twelve-month figure through Mar 2026 was -$228000.0 (down 100.19% YoY), and the FY2025 annual result was $53.5 million, down 40.73% from the prior year.
• Cash from Investing Activities came in at $8.5 million for Q1 2026 at Prelude Therapeutics, up from -$60.3 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $62.2 million in Q1 2025 to a low of -$75.4 million in Q2 2023.
• The 5-year median for Cash from Investing Activities is $15.0 million (2023), against an average of $11.7 million.
• Across the five-year window, Cash from Investing Activities soared 15474.28% in 2022 and plunged 372.8% in 2025, its largest moves.
• Prelude Therapeutics' Cash from Investing Activities stood at $1.4 million in 2022, then jumped by 470.92% to $7.7 million in 2023, then surged by 185.91% to $22.1 million in 2024, then slumped by 372.8% to -$60.3 million in 2025, then soared by 114.09% to $8.5 million in 2026.
• The last three Cash from Investing Activities figures came in at $8.5 million (Q1 2026), -$60.3 million (Q4 2025), and $40.1 million (Q3 2025), per Business Quant data.